CRL vs TRNS · rev $2.00B vs P/E 57, rev $92.9M
Charles River Laboratories (CRL) versus Transcat Inc (TRNS) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Transcat Inc (TRNS) is a specialty business services company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported TRNS revenue for 2026-06-27 was $92.9M. Net income was $1.3M. Revenue was down 61.7% from 2025-12-27 to 2026-06-27. TRNS currently screens at market cap $837.5M and trailing P/E 57.2.
CRL currently screens at market cap $7.78B. TRNS currently screens at market cap $837.5M and trailing P/E 57.2.
Not investment advice. Open the CRL and TRNS stock pages for the full models.
Not investment advice.